X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. It is being evaluated for recurrent glioblastoma.
Lead Product(s): VBI-1901
Therapeutic Area: Oncology Product Name: VBI-1901
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
VBI Vaccines and the Canadian government broaden the scope of longstanding to accelerate the development of VBI’s novel, mRNA-launched enveloped virus-like particle vaccine for the treatment of cytomegalovirus infection and Epstein-Barr virus.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Government of Canada
Deal Size: $41.2 million Upfront Cash: Undisclosed
Deal Type: Partnership April 02, 2024
Details:
Through the acquisition, Brii will get access to focus on the development of VBI-2601 (BRII-179), a protein-based HBV immunotherapeutic candidate intended for the treatment of chronic HBV infection.
Lead Product(s): BRII-179,Elebsiran
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Brii Biosciences
Deal Size: $33.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition February 13, 2024
Details:
The new mRNA-launched eVLP (MLE) technology has demonstrated an ability to generate stronger B- and T-cell signals than those seen with other mRNA vaccines tested, which will be investigated for cytomegalovirus (CMV), Epstein-Barr virus (EBV), and coronaviruses.
Lead Product(s): mRNA-Based eVLP Vaccine Platform
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65.
Lead Product(s): VBI-1901
Therapeutic Area: Oncology Product Name: VBI-1901
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.
Lead Product(s): BRII-179,VIR-2218
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Brii Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
The proceeds will fund the commercialization activities for PreHevbrio [Hepatitis B Vaccine (Recombinant)] in the US, Europe, and Canada; and ongoing activities of development stage candidates, including VBI-1901 (glioblastoma) and VBI-2901 (coronaviruses).
Lead Product(s): Recombinant Hepatitis B Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: PreHevbrio
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 24, 2023
Details:
The proceeds will fund the commercialization for PreHevbrio [Hepatitis B Vaccine (Recombinant)] in the US, Europe, and Canada, manufacturing of PreHevbrio for its pipeline programs, and ongoing activities related to VBI-1901 (glioblastoma) and VBI-2901 (coronaviruses).
Lead Product(s): Recombinant Hepatitis B Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: PreHevbrio
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 06, 2023
Details:
The proceeds will fund the commercialization for PreHevbrio (recombinant hepatitis B vaccine) in the US, Europe, and Canada, manufacturing of PreHevbrio for its pipeline programs, and ongoing activities related to VBI-1901 (glioblastoma) and VBI-2901 (coronaviruses).
Lead Product(s): Recombinant Hepatitis B Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: PreHevbrio
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 05, 2023
Details:
Under the collaboration, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri, VBI’s 3-antigen hepatitis B vaccine, in the Asia Pacific region (APAC).
Lead Product(s): BRII-179
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Brii Biosciences
Deal Size: $437.0 million Upfront Cash: $15.0 million
Deal Type: Expanded Collaboration July 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
